AU6465598A - Hla-binding peptides and their uses - Google Patents

Hla-binding peptides and their uses Download PDF

Info

Publication number
AU6465598A
AU6465598A AU64655/98A AU6465598A AU6465598A AU 6465598 A AU6465598 A AU 6465598A AU 64655/98 A AU64655/98 A AU 64655/98A AU 6465598 A AU6465598 A AU 6465598A AU 6465598 A AU6465598 A AU 6465598A
Authority
AU
Australia
Prior art keywords
peptide
pct
peptides
hpv
prost
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU64655/98A
Other languages
English (en)
Inventor
Esteban Celis
Howard M. Grey
Ralph T. Kubo
Alessandro Sette
John Sidney
Scott Southwood
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Epimmune Inc
Original Assignee
Epimmune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epimmune Inc filed Critical Epimmune Inc
Publication of AU6465598A publication Critical patent/AU6465598A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/36—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Actinomyces; from Streptomyces (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU64655/98A 1998-03-13 1998-03-13 Hla-binding peptides and their uses Abandoned AU6465598A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US1998/005039 WO1999045954A1 (en) 1998-03-13 1998-03-13 Hla-binding peptides and their uses

Publications (1)

Publication Number Publication Date
AU6465598A true AU6465598A (en) 1999-09-27

Family

ID=22266589

Family Applications (1)

Application Number Title Priority Date Filing Date
AU64655/98A Abandoned AU6465598A (en) 1998-03-13 1998-03-13 Hla-binding peptides and their uses

Country Status (5)

Country Link
EP (1) EP1064022A4 (ja)
JP (1) JP2002507397A (ja)
AU (1) AU6465598A (ja)
CA (1) CA2323632A1 (ja)
WO (1) WO1999045954A1 (ja)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7611713B2 (en) 1993-03-05 2009-11-03 Pharmexa Inc. Inducing cellular immune responses to hepatitis B virus using peptide compositions
US9340577B2 (en) 1992-08-07 2016-05-17 Epimmune Inc. HLA binding motifs and peptides and their uses
US6291430B1 (en) 1997-09-12 2001-09-18 Ludwig Institute For Cancer Research Mage-3 peptides presented by HLA class II molecules
US6716809B1 (en) 1997-09-12 2004-04-06 Ludwig Institute For Cancer Research Mage-A3 peptides presented by HLA class molecules
US6183746B1 (en) 1997-10-09 2001-02-06 Zycos Inc. Immunogenic peptides from the HPV E7 protein
US6407063B1 (en) 1998-10-02 2002-06-18 Ludwig Institute For Cancer Research Tumor antigens and CTL clones isolated by a novel procedure
WO2000020445A2 (en) * 1998-10-02 2000-04-13 Ludwig Institute For Cancer Research Tumor antigens and ctl clones isolated by a novel procedure
US6541214B1 (en) * 1998-11-13 2003-04-01 Oregon Heath Science University N-terminally truncated HER-2/neu protein as a cancer prognostic indicator
GB9826143D0 (en) 1998-11-27 1999-01-20 Ludwig Inst Cancer Res Tumour rejection antigens
KR20010080661A (ko) * 1998-12-01 2001-08-22 교고 이또 신규의 종양 항원 단백질 ａｒｔ-1 및 이의 종양 항원펩티드
IT1309584B1 (it) * 1999-02-26 2002-01-24 San Raffaele Centro Fond Peptidi immunogenici derivati da mage-3 presentati da mhc di classeii e loro uso.
WO2001032193A1 (en) * 1999-10-29 2001-05-10 Argonex Pharmaceuticals Cytotoxic t lymphocyte-stimulating peptides for prevention, treatment, and diagnosis of melanoma
CA2386341A1 (en) * 1999-11-18 2001-05-25 Epimmune Inc. Heteroclitic analogs and related methods
CA2393738A1 (en) * 1999-12-10 2001-06-14 Epimmune Inc. Inducing cellular immune responses to her2/neu using peptide and nucleic acid compositions
US7026443B1 (en) * 1999-12-10 2006-04-11 Epimmune Inc. Inducing cellular immune responses to human Papillomavirus using peptide and nucleic acid compositions
JP2003516131A (ja) * 1999-12-10 2003-05-13 エピミューン， インコーポレイテッド ペプチドおよび核酸組成物を使用する、ｐ５３に対する細胞性免疫応答の誘導
EP1235841A4 (en) * 1999-12-10 2006-04-12 Epimmune Inc TRIGGERING MAGE2 / 3 CELLULAR IMMUNE RESPONSES USING PEPTIDE AND NUCLEIC ACID COMPOSITIONS
EP1244465A4 (en) * 1999-12-21 2005-01-12 Epimmune Inc INDUCTION OF CELLULAR IMMUNE RESPONSE TO PROSTATE CANCER BY MEANS OF PEPTIDE AND NUCLEIC ACID COMPOUNDS
US7462354B2 (en) 1999-12-28 2008-12-09 Pharmexa Inc. Method and system for optimizing minigenes and peptides encoded thereby
FR2806727A1 (fr) * 2000-03-23 2001-09-28 Pf Medicament Molecule d'interet pharmaceutique comprotant en son extremite n-terminale un acide glutamique ou une glutamine sous forme de sel d'addition d'acide fort physiologiquement acceptable
AU2001253029A1 (en) * 2000-03-30 2001-10-15 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services T-cell epitope of mage-12 and related nucleic acids, vectors, cells, compositions and methods of inducing an immune response to cancer
CN1107681C (zh) * 2000-08-11 2003-05-07 中国科学院微生物研究所 乙肝病毒抗原多肽与热休克蛋白的复合物及其应用
JP2004522412A (ja) * 2000-08-14 2004-07-29 コリクサ コーポレイション Ｈｅｒ−２／ｎｅｕ−関連悪性腫瘍の治療および診断のための組成物および方法
EP1313505A4 (en) * 2000-09-01 2005-10-12 Epimmune Inc HLA BINDING PEPTIDES AND THEIR USES (18.03.02)
EP1195381A1 (de) * 2000-09-28 2002-04-10 Immusystems GmbH CD4+ T-Lymphozyten spezifische Hepatitis C Virus-Epitope
WO2002042325A2 (en) 2000-10-31 2002-05-30 Zycos Inc. Cyp1b1 nucleic acids and methods of use
CA2439990A1 (en) * 2001-03-01 2002-09-12 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, Centers For Disease Control And Prevention, Technology Transfer Office Immunogenic hiv peptides for use as reagents and vaccines
US7252824B2 (en) * 2001-03-07 2007-08-07 Mannkind Corporation Anti-neovasculature preparations for cancer
EP1752160A3 (en) * 2001-04-06 2007-05-30 Mannkind Corporation Epitope sequences
WO2003008537A2 (en) * 2001-04-06 2003-01-30 Mannkind Corporation Epitope sequences
AU2002305138A1 (en) 2001-04-09 2002-10-21 Mayo Foundation For Medical Education And Research Methods and materials for cancer treatment
US20060222656A1 (en) 2005-04-01 2006-10-05 University Of Maryland, Baltimore MAGE-A3/HPV 16 peptide vaccines for head and neck cancer
US7049413B2 (en) 2001-05-18 2006-05-23 Ludwig Institute For Cancer Research MAGE-A3 peptides presented by HLA class II molecules
WO2002094994A2 (en) 2001-05-18 2002-11-28 Mayo Foundation For Medical Education And Research Chimeric antigen-specific t cell-activating polypeptides
EP1531860A4 (en) * 2001-06-05 2005-11-02 Us Gov Health & Human Serv PEPTIDES FOR THE DIAGNOSIS OF CHLAMYDOPHILA PNEUMONIAE AND THE VACCINE AGAINST CHLAMYDOPHILA PNEUMONIAE
US20030113919A1 (en) * 2001-08-17 2003-06-19 Aventis Pasteur, Ltd. Immunogenic targets for melanoma
CA2357906A1 (en) 2001-09-28 2003-03-28 Institut Pasteur Identification of new cd8 epitopes from hiv-1 proteins with therapeutical and vaccinal properties against hiv infections
DE60238864D1 (de) * 2001-11-07 2011-02-17 Mankind Corp Für epitope von antigenen kodierende expressionsvektoren und verfahren zu deren konzeption
EP1462456A4 (en) * 2001-12-10 2005-09-21 Greenpeptide Co Ltd TUMOR ANTIGENS
WO2003087126A2 (en) * 2002-04-05 2003-10-23 Epimmune Inc. Heteroclitic analogs and related methods
EP2336189A1 (en) 2003-01-28 2011-06-22 Proscan RX Pharma Prostate cancer diagnosis and treatment
JPWO2005007694A1 (ja) * 2003-07-16 2007-09-20 株式会社グリーンペプタイド ＨＥＲ２／ｎｅｕペプチドおよびその治療上の用途
JP5097400B2 (ja) * 2003-09-03 2012-12-12 デンドリセラピューティクス、インク． 複合ワクチン
US7488793B2 (en) * 2003-09-22 2009-02-10 Ludwig Institute For Cancer Research Isolated peptide which binds to HLA-Cw*07 and uses thereof
EP2062590A1 (en) * 2003-09-22 2009-05-27 Green Peptide Co., Ltd. Peptide derived from Hepatitis C virus
US9090673B2 (en) 2003-12-12 2015-07-28 City Of Hope Synthetic conjugate of CpG DNA and T-help/CTL peptide
GB0716992D0 (en) 2007-08-31 2007-10-10 Immune Targeting Systems Its L Influenza antigen delivery vectors and constructs
GB0408164D0 (en) 2004-04-13 2004-05-19 Immune Targeting Systems Ltd Antigen delivery vectors and constructs
WO2005103679A2 (en) 2004-04-21 2005-11-03 Algonomics Nv Method for affinity scoring of peptide/protein complexes
EP1757687A4 (en) * 2004-04-30 2008-01-16 Nec Corp HLA BINDING PEPTIDE, PRE-STEP, DNA DOMAGING AND RECOMBINANT VECTOR
WO2006035681A1 (ja) * 2004-09-27 2006-04-06 National University Corporation Tokyo Medical And Dental University ＨＬＡ－Ａ１１拘束性Ｔａｘ抗腫瘍エピトープ
JP5116150B2 (ja) * 2005-09-07 2013-01-09 日本電気株式会社 Ｈｌａ結合性ペプチド、それをコードするｄｎａ断片および組み換えベクター
WO2007120834A2 (en) 2006-04-13 2007-10-25 Peptimmune, Inc. Methods for designing and synthesizing directed sequence polymer compositions via the directed expansion of epitope permeability
WO2008010010A1 (en) * 2006-07-12 2008-01-24 Vaxon Biotech Identification, optimization and use of cryptic hla-b7 epitopes for immunotherapy
EP2586460A1 (en) 2007-10-16 2013-05-01 Peptimmune, Inc. Method for designing and preparing vaccines comprising directed sequence polymer composition via the directed expansion of epitopes
US8728492B2 (en) 2008-01-18 2014-05-20 Aeras Global Tb Vaccine Foundation Malaria vaccine compositions and constituents which elicit cell mediated immunity
WO2010086294A2 (en) 2009-01-28 2010-08-05 Epimmune Inc. Pan-dr binding polypeptides and uses thereof
CA2775720A1 (en) * 2009-09-30 2011-04-07 Saint Louis University Peptides for inducing heterosubtypic influenza t cell responses
JP5930967B2 (ja) * 2010-09-08 2016-06-08 学校法人 埼玉医科大学 Ｃ型肝炎ウイルスリポソームワクチン
JP6130307B2 (ja) 2011-03-17 2017-05-17 ザ ユニバーシティ オブ バーミンガム 再指向性免疫療法
CN102286075A (zh) * 2011-08-01 2011-12-21 中国人民解放军第三军医大学 乙肝病毒表面抗原的免疫显性hla-a*1101限制性ctl表位及其应用
EP3444262A3 (en) * 2011-09-09 2019-04-10 Agency For Science, Technology And Research P53 activating peptides
AU2013210783B2 (en) * 2012-01-20 2017-12-07 Cellvax Therapeutics Inc. Autologous cancer cell vaccine
JP5999703B2 (ja) * 2013-01-09 2016-09-28 国立大学法人 東京医科歯科大学 ＨＬＡ−ＤＲ１拘束性Ｔａｘ特異的ＣＤ４＋Ｔ細胞エピトープ
WO2016131856A1 (en) * 2015-02-18 2016-08-25 F. Hoffmann-La Roche Ag Immunoconjugates for specific induction of t cell cytotoxicity against a target cell
CN105037559B (zh) * 2015-08-17 2018-09-25 北京康爱瑞浩生物科技股份有限公司 治疗或预防乙肝的细胞毒性t淋巴细胞及其制备方法
TWI796642B (zh) 2015-08-28 2023-03-21 德商英麥提克生物技術股份有限公司 用於多種癌症之免疫治療的新穎胜肽、胜肽的組合物及支架
GB201515321D0 (en) 2015-08-28 2015-10-14 Immatics Biotechnologies Gmbh Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers
CN111148528A (zh) 2016-12-28 2020-05-12 英福瓦克思公司 流感疫苗
US11517591B2 (en) 2017-09-01 2022-12-06 Dana-Farber Cancer Institute, Inc. Immunogenic peptides specific to BCMA and TACI antigens
EP3545967A1 (en) * 2018-03-28 2019-10-02 Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts Cancer immunization platform
US20230087348A1 (en) * 2019-01-11 2023-03-23 Agency For Science, Technology And Research Use of hla-a*11:01-restricted hepatitis b virus (hbv) peptides for identifying hbv-specific cd8+ t cells
BR112021017404A2 (pt) * 2019-03-04 2022-02-01 Univ Health Network Receptores de células t e métodos de uso dos mesmos

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2141960A1 (en) * 1992-08-07 1994-02-17 Ralph T. Kubo Hla binding peptides and their uses
US20020168374A1 (en) * 1992-08-07 2002-11-14 Ralph T. Kubo Hla binding peptides and their uses
BR9708161A (pt) * 1996-03-11 1999-07-27 Epimmune Inc Peptídeos com aumentada afinidade de ligação para moléculas hla
BR9708220A (pt) * 1996-03-21 2000-01-04 Epimmune Inc Peptìdios de ligação hla-a2.1 e seus usos
US6413517B1 (en) * 1997-01-23 2002-07-02 Epimmune, Inc. Identification of broadly reactive DR restricted epitopes

Also Published As

Publication number Publication date
CA2323632A1 (en) 1999-09-16
EP1064022A1 (en) 2001-01-03
EP1064022A4 (en) 2004-09-29
JP2002507397A (ja) 2002-03-12
WO1999045954A1 (en) 1999-09-16

Similar Documents

Publication Publication Date Title
AU6465598A (en) Hla-binding peptides and their uses
US7252829B1 (en) HLA binding peptides and their uses
AU725550B2 (en) HLA binding peptides and their uses
CA2248667C (en) Hla-a2.1 binding peptides and their uses
EP1917970B1 (en) Hla binding peptides and their uses
CA2400215A1 (en) Hla binding peptides and their uses
US20030152580A1 (en) Hla binding peptides and their uses
US20020177694A1 (en) Hla binding peptides and their uses
EP1089757B1 (en) Hla binding peptides and their uses
EP1343819A1 (en) Hla-a2.1 binding peptides and their uses
EP1320377B1 (en) Hla binding peptides and their uses
EP1767542B1 (en) HLA-A2.1 binding peptides and their uses
WO2002020053A1 (en) Hla binding peptides and their uses
KR20030036139A (ko) Ｈｌａ 결합 펩티드 및 이의 용도
JP2010001303A (ja) Ｈｌａ結合ペプチド及びその使用

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period